This article is more than 5 years old. Information may no longer be current.
Cabozantinib prolonged PFS in patients with MTC
Click Here to Manage Email Alerts
QUEBEC CITY — Cabozantinib significantly extended PFS in patients with progressing medullary thyroid carcinoma, according to results of a randomized phase 3 study.
Manisha H. Shah, MD, associate professor for the experimental therapeutics research program at Ohio State University Comprehensive Cancer Center, and colleagues enrolled 330 patients with medullary thyroid carcinoma.
The researchers randomly assigned patients to cabozantinib (XL184, Exelixis; n=219) or placebo (n=111). The patients assigned to the study drug received 140 mg daily.
PFS served as the primary endpoint.
At the time of primary endpoint analysis, median PFS was 11.2 months among patients assigned to cabozantinib compared with 4 months for patients assigned to placebo (HR=0.28; 95% CI, 0.19-0.40).
PFS results favored cabozantinib across all patient subgroups, the researchers said.
Researchers also evaluated patients based on RET mutation status. The investigators calculated HRs of 0.24 for patients with positive mutation status, 0.47 for patients with negative mutation status, and 0.3 for patients with unknown mutation status.
The overall response rate among patients in the cabozantinib group was 28% compared with 0% for the placebo group (P<.0001). The objective response rate was consistent across all subgroups.
For more information:
Shah MH. Abstract # 17. Presented at: the American Thyroid Association 82nd Annual Meeting; Sept. 19-23; Quebec City.
Disclosure: The researchers report employment and consulting relationships with Exelixis.